91 related articles for article (PubMed ID: 9181467)
1. Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein.
Babé LM; Unal A; Craik CS
J Interferon Cytokine Res; 1997 May; 17(5):287-93. PubMed ID: 9181467
[TBL] [Abstract][Full Text] [Related]
2. Interferon treatment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins.
Agy MB; Acker RL; Sherbert CH; Katze MG
Virology; 1995 Dec; 214(2):379-86. PubMed ID: 8553538
[TBL] [Abstract][Full Text] [Related]
3. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid.
Wiegers K; Rutter G; Schubert U; Grättinger M; Kräusslich HG
Virology; 1999 Apr; 257(1):261-74. PubMed ID: 10208939
[TBL] [Abstract][Full Text] [Related]
4. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
DaFonseca S; Blommaert A; Coric P; Hong SS; Bouaziz S; Boulanger P
Antivir Ther; 2007; 12(8):1185-203. PubMed ID: 18240859
[TBL] [Abstract][Full Text] [Related]
5. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
[TBL] [Abstract][Full Text] [Related]
6. In vitro processing of human immunodeficiency virus type 1 Gag virus-like particles.
Morikawa Y; Shibuya M; Goto T; Sano K
Virology; 2000 Jul; 272(2):366-74. PubMed ID: 10873780
[TBL] [Abstract][Full Text] [Related]
7. The role of nucleocapsid of HIV-1 in virus assembly.
Dawson L; Yu XF
Virology; 1998 Nov; 251(1):141-57. PubMed ID: 9813210
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 gag proteins: diverse functions in the virus life cycle.
Freed EO
Virology; 1998 Nov; 251(1):1-15. PubMed ID: 9813197
[TBL] [Abstract][Full Text] [Related]
9. A human cell line constitutively expressing HIV-1 Gag and Gag-Pol gene products.
Wang CT; Li JJ; Lai HY; Hu BS
J Med Virol; 1999 Jan; 57(1):17-24. PubMed ID: 9890417
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.
Müller B; Daecke J; Fackler OT; Dittmar MT; Zentgraf H; Kräusslich HG
J Virol; 2004 Oct; 78(19):10803-13. PubMed ID: 15367647
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type 1 assembly, release, and maturation.
Adamson CS; Freed EO
Adv Pharmacol; 2007; 55():347-87. PubMed ID: 17586320
[No Abstract] [Full Text] [Related]
13. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
14. Organization of immature human immunodeficiency virus type 1.
Wilk T; Gross I; Gowen BE; Rutten T; de Haas F; Welker R; Kräusslich HG; Boulanger P; Fuller SD
J Virol; 2001 Jan; 75(2):759-71. PubMed ID: 11134289
[TBL] [Abstract][Full Text] [Related]
15. The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles.
Chen SW; Chiu HC; Liao WH; Wang FD; Chen SS; Wang CT
Virology; 2004 Jan; 318(2):534-41. PubMed ID: 14972522
[TBL] [Abstract][Full Text] [Related]
16. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
17. Interferon downregulates CXCR4 (fusin) gene expression in peripheral blood mononuclear cells.
Shirazi Y; Pitha PM
J Hum Virol; 1998; 1(2):69-76. PubMed ID: 10195234
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
